Institute of Life Sciences, Bhubaneswar, Odisha, India.
Institute of Life Sciences, Bhubaneswar, Odisha, India.
Drug Discov Today. 2020 Aug;25(8):1307-1321. doi: 10.1016/j.drudis.2020.06.003. Epub 2020 Jun 15.
Research suggests that tumor relapse and metastasis is caused by minor population of tumor-initiating cells called cancer stem cells (CSCs), which exhibit self-renewability, quiescence, antiapoptosis, and drug resistance. Conventional chemotherapeutics target rapidly proliferating cells but fail to exert cytotoxic effects on CSCs, thus enriching them and driving metastasis and relapse. Hence, targeting CSCs is essential for developing novel therapies for effective cancer treatment. Pertaining to this, several phytochemicals have been identified that exhibit anti-CSC activity. However, poor pharmacokinetics prevents their clinical translation. Hence, developing phytonanomedicine can help to improve the pharmacokinetic profile of these biologically active molecules. In this review, we summarize the current state of the art of phytonanomedicine in the context of CSCs and their clinical status in cancer treatment.
研究表明，肿瘤的复发和转移是由一小部分被称为肿瘤起始细胞（CSCs）的肿瘤细胞引起的，这些细胞表现出自更新、静止、抗凋亡和耐药性。传统的化疗药物针对快速增殖的细胞，但对 CSCs 没有细胞毒性作用，从而使它们富集，并导致转移和复发。因此，针对 CSCs 是开发新型癌症治疗有效疗法的关键。为此，已经鉴定出几种具有抗 CSC 活性的植物化学物质。然而，较差的药代动力学特性阻止了它们的临床转化。因此，开发植物纳米医学可以帮助改善这些生物活性分子的药代动力学特性。在这篇综述中，我们总结了植物纳米医学在 CSCs 方面的最新进展及其在癌症治疗中的临床现状。
